Archive 2009
31st March 2009. EUSA Pharma announced today the successful completion of its European launch of Caphosol® for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care.
18th March 2009. EUSA Pharma announced today the appointment of David Cook to the newly-created role of Chief Financial Officer
22nd January 2009. At its Gala Dinner, the BioIndustry Association (BIA) presented the sixth BIA Award for Outstanding Personal Contribution to UK Bioscience to Rolf Stahel.
Archive 2008
28th October 2008. EUSA Pharma is pleased to announce the appointment of
Nigel Pitchford, MA MBA PhD to the EUSA Pharma Board of Directors
9th May 2008. EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May
1st May 2008. EUSA Pharma announces that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). therapeutic research program for acute lymphoblastic leukemia
Concurrently, EUSA divests its recombinant L-asparaginase to the Alizé Pharma Group
11 March 2008. EUSA Pharma to Acquire US Specialty Oncology Company Cytogen, raising $50 million to fund the acquisition and other investments
25 February 2008. Novel Rapydan® gains Marketing Authorisation in EU for the Relief of Pain associated with Needle Puncture and Cannulation
18 February 2008. EUSA Pharma out-licences preclinical-stage human antibody to GlaxoSmithKline for up to $44 million plus royalties
Archive 2007
18 October 2007.
EUSA Pharma announces the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007.
3 October 2007. EUSA Pharma appoints Ad van Beysterveldt as President Europe and member of the company’s Executive Committee.
23 August 2007. EUSA Pharma today announced the acquisition ofthe assets of Innocoll Inc (“Innocoll”).
1 March 2007. EUSA Pharma announces the acquisition of OPi SA (OPi), an integrated biopharmaceutical company.
28 February 2007. EUSA Pharma announces the appointment of Dr Simon Clough as General Manager for the UK, Ireland and Scandinavia region.
26 January 2007. The Swedish Medical Products Agency grants marketing authorisation for Rapydan ®, an advanced topical anaesthetic plaster.
2 January 2007. EUSA Pharma appoints Paul Davisson as head of supply chain management, Europe.
1 January 2007. EUSA Pharma strengthened its board, announcing the appointment of Rolf Stahel as Chairman, William (Bill) Crouse and Göran Ando as non-executive Directors.
|